Lumos Diagnostics Holdings Limited
Bell Potter Healthcare Conference

20 November 2024

Financial information is shown in USD unless otherwise stated.

lumosdiagnostics.com

Disclaimer and Important Information

This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited (Company).

The information contained in this document ("Document") has been prepared by Lumos Diagnostics Holdings Limited (referred to as "Lumos" or "Company"). This Document is current as at the date of this Document and should be read in conjunction with other Lumos periodic and continuous disclosure announcements filed with the Australian Securities Exchange (ASX), available at www.asx.com.au.

The information in this Document is not intended to form the basis of any investment decision in relation to the Company or its assets and should not be considered as a recommendation to the Recipient to acquire securities in the Company. This Document is not a prospectus, profile statement or disclosure document and does not constitute an offer or invitation to acquire securities or otherwise invest in the Company, and no agreement to subscribe for securities will be entered into on the basis of this Document.

No representation or warranty, expressed or implied, is or will be made, and no responsibility or liability is or will be accepted by the Company, any of their respective officers, servants, agents or advisers (collectively "Limited Parties") as to or in relation to the accuracy, reasonableness, completeness or reliability of the information in this Document or any other written or oral information made available to any Recipients or their advisers. Any liability therefore is hereby expressly disclaimed. In particular, no representation or warranty is given as to the achievability or reasonableness of any future projections, management estimates or plans, prospects, returns or forecasts.

To the fullest extent permitted by law, the Limited Parties will not have any responsibility or liability for any loss or damage (whether foreseeable or not), however arising (including as a result of negligence), in relation to or in connection with the provision of this Document, the Recipient's or any other person's purported reliance on this Document, the failure to provide information of which any of the Limited Parties becomes aware or any errors in or omissions from this Document.

None of the Limited Parties makes or gives any representation, warranty or guarantee, express or implied, that the information in this Document is accurate, current, reliable or complete, has been or will be audited or independently verified, or that reasonable care has been taken in compiling, preparing or furnishing it. Various statements in this Document constitute statements relating to intentions, future acts and events including forecast financial information ("Forward Looking Statements"). Forward Looking Statements involve subjective judgment and analysis, known and unknown risks, uncertainties and other important factors that may cause those future acts, events and circumstances to differ from the way or manner in which they are expressly or impliedly portrayed herein.

The Limited Parties do not make or give any representation, warranty or guarantee, express or implied, that any Forward Looking Statements will be achieved or proven correct, or that any assumptions or projections on which the Forward Looking Statements are based are reasonable. No historical financial information, forecast financial information, estimates or projections contained in this Document or any other financial information derived from that information, can be relied upon as a promise or representation, as to the past, present or the future. Past performance is not necessarily a guide to future likelihood of achievement or reasonableness of any Forward Looking Statement, forecast financial information or other forecast. The Limited Parties do not undertake any obligation to (and expressly disclaim any obligation to) provide the Recipients with access to any additional information or to correct any inaccuracies herein which may become apparent or to disseminate any updates or revisions to any Forward Looking Statements in this Document to reflect any change in expectations in relation to any such statements or any change in events, conditions or circumstances on which any such statement is based.

This document also contains statistics, data and other information relating to markets, market sizes, market shares, market positions and other industry data pertaining to the Lumos business and markets. Such information is generally based on independent market and industry data or research. Lumos has not independently verified and cannot give any assurances as to the accuracy and completeness of the information sourced from market and industry data or research contained herein. Accordingly, the accuracy and completeness of such information is not guaranteed. There is no assurance that any of the forecasts or projections contained in the independent market and industry data or research will be achieved. Forecasts and projections involve risks and uncertainties and are subject to change based on various factors. You should note that market data and statistics are inherently predictive and subject to uncertainty and not necessarily reflective of actual market conditions.

Neither the receipt of this Document by any person nor any information contained in it or supplied with it or subsequently communicated to any person in connection with a proposed investment in the Company constitutes, or is to be taken as constituting, the giving of investment or financial product advice (or any other advice) to any such person. Each such person should make their own independent assessment of the merits or otherwise of investing in the Company and should seek their own professional advice in respect of any future investment opportunity and not act on the basis of any matter contained in this Document. In providing this Document, the Company has not considered the objectives, financial position, taxation situation or other needs of any particular Recipient.

The distribution of this document in jurisdictions outside Australia may be restricted by law. Persons who come into possession of this document who are not in Australia, should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. In particular, this document does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States.

Non-IFRS financial measures

Recipients should note that certain financial data included in this Document is not recognised under the AAS and is classified as 'non-IFRS financial information' under Regulatory Guide 230 'Disclosing non-IFRS financial information' published by ASIC. The Company believes that this non-IFRS financial information provides useful information to users in measuring the financial performance and condition of Lumos. The non-IFRS financial measures do not have standardised meanings under AAS, and therefore may not be comparable with similarly titled measures presented by other entities, nor should these be interpreted as an alternative to other financial measures determined in accordance with AAS. Investors are cautioned not to place undue reliance on any non-IFRS financial information, ratios and metrics included in this Document.

Improving the Practice of Medicine

Lumos is a developer and manufacturer of rapid point-of-care tests and instruments for the diagnostics and healthcare industries

Launched Unique test to forever change treatment of acute respiratory infection

- FebriDx - Detection of acute respiratory infections - differentiation of bacterial and non-bacterial etiology
- ViraDx – Detection of Covid 19, Influenzas A, and Influenzas B



Improve women's health through access to rapid testing at the point of care

- Developing first in class rapid testing for detecting infections
- Future portfolio for testing to improve women's health



Selected partner for world’s largest women's healthcare company, Hologic

- Development and manufacturing services for Hologic’s proprietary fFn point-of-care test and proprietary digital reader platform.

Company Snapshot

Issued Capital	
Shares	745.8m
Options	143.9m
Market Capitalization (AUD)	
Share price[1]	A$0.032
Market value	A$23.9m
Pro-forma Cash (30 September 2024 – in AUD)[2]	A$14.8m
Enterprise value	A$9.1m
Substantial shareholders	
Tenmile Ventures	19.9%
Ryder Capital	17.0%
Planet Innovation	3.1%

Share Price & Volume



Board and Management	
Sam Lanyon	Non-Executive Chairman
Doug Ward	CEO & Managing Director
Bronwyn Le Grice	Non-Executive Director
Lawrence Mehren	Non-Executive Director
Catherine Robson	Non-Executive Director
Barrie Lambert	Chief Financial Officer

[1]As at 15 November 2024

[2] Pro-forma cash as at 30 September 2024 after capital raising of A$10.0 million. US$9.8 million, as per Q1 FY25 activities report at an FX rate of 0.66.

FebriDx: First-of-its-Kind Point-of-Care Test

FebriDx offers an aid for healthcare providers to improve patient care and antibiotic stewardship

- Antibiotics often prescribed for respiratory infections unnecessarily (ie. patient had no bacterial infection)[1]
- Antibiotics can result in adverse patient reactions and contribute to antimicrobial drug resistance

FebriDx regulatory clearances and commercial activities

- 708-subject, multicentre clinical trial published in JAMA in 2022 — 98.7% NPV for bacterial infections
- FebriDx cleared in the US[2], Europe, UK, Australia and other markets
- Clearance to market FebriDx in the US awarded in July 2023, as “moderate-complex” test

CLIA Waiver will Expand FebriDx Market Opportunity in the US > $1Billion

MODERATE COMPLEXITY LIMITATION

Potential Customer Sites



■ Moderate Complex

- 18,000[2] potential customer sites in US
- Acute Respiratory Infections (ARI) in US Annually: 80 million (potential FebriDx patient opportunities for use)[1]
- Moderate complex settings ~7% (5.6 million patient interactions)
- Assume distributor sell price to end customers of US$21.00 (CPT codes for reimbursement is US$29.55)
- TAM US$118 million p.a.

15x

CLIA WAIVER EXPANDS ADDRESSABLE MARKET

Potential Customer Sites



■ CLIA Waived

- 270,000[2] potential customer sites in US
- Acute Respiratory Infections (ARI) in US Annually: 80 million (potential FebriDx patient opportunities for use)[1]
- CLIA waiver enables 100% market coverage (80 million patient interactions)
- Assume distributor sell price to end customers of US$21.00 (CPT codes for reimbursement is US$29.55)
- TAM US$1.7 billion p.a.

[1] Source from 2024 Precision Business Insights Report for periods 2026-2030.
[2] Division of Clinical Laboratory Improvement and Quality Centers for Medicare & Medicaid Services, March 2024 (CMS CLIA Data base)

Lumos and BARDA to Partner to Support FebriDx® bacterial/non-bacterial point-of-care test CLIA Waiver Study and Application

Key highlights

- BARDA has awarded Lumos with US$2.984m in non-dilutive funding to support the CLIA waiver study and US FDA application
    - Payment over the next 12 months based on milestone achievements
    - The partnership aims to expand authorized testing to CLIA-waived, point-of-care settings, including U.S. physician offices, urgent care clinics, or other outpatient clinics, where empiric antibiotic prescription is common practice
    - BARDA will support the CLIA waiver study, comparing test usage among untrained users in a CLIA-waived setting to trained users and provide regulatory expertise and support for the application to obtain a CLIA-waiver from the FDA
- Total contract value, if all contract options are exercised, is US$8.258m
    - Option value of US$5.274m is to support FebriDx expanded claim for patients under 12 years of age
    - Assuming option is exercised (anticipated mid-calendar 2025), payment to be over 12-18 months based on milestone achievement

ViraDx™ – Point-of-Care test for key respiratory infections

- **FDA –** Emergency Use Authorisation and CLIA waiver September 2023
- **Highly relevant test** for post-pandemic environment
- **3-in-1 test** for COVID-19/Flu A/Flu B
- **27 partnership** distribution agreements

Products - Lumos Product Roadmap | Women's Sexual Health - $10B

PREVALENCE

30-40% of women
>10M heath care visits annually



CLINICAL NEED

Multiple infectious organisms
Similar symptoms
Different treatments

POC DIAGNOSTIC NEED

Rapid testing on site
Identify & treat at patient visit
Easy to use by clinic staff

Hologic - new major development and IP agreements

Focus on improving one of Hologic's leading on-market women's health products and adapting it for use on Lumos' proprietary reader platform.

Fetal fibronectin

- Development of next generation point of care technologies and intellectual property rights for reader
- fFN is protein found at the maternal-fetal interface. As delivery approaches, fFN is increasingly detectable
- Detection of fFN (in pregnancy weeks 22 – 35) can indicate that a woman is at higher risk of preterm delivery
- Positive fFN result indicates an increased risk of delivery in the next 14 days

IP agreement payments

- Valued at US$10M in two equal non-refundable payments by June 2024

Development agreement payments

- Valued at up to US$4.7M in payments over an 18-24 month period upon achieving milestones

Hologic - fFN product development overview

Current test: Rapid fFN TLiQ

Next generation test concept (mock-up)

Benefits of the new technology

- Latest state-of-the-art technology, with reader platform
- Connectivity for improved digital patient record management
- Developed and manufactured to latest GMP quality standards

Priority Catalysts for Growth

With a strong pipeline of projects & partnerships and balance sheet strength, supported by the recent capital raise, we are well-positioned for continued growth and success.

Doug Ward
MD & Chief Executive Officer
Lumos Diagnostics

Monetize the Lumos-owned, cleared point-of-care test products: FebriDx and ViraDx, through sales, licenses and partnerships

Complete a successful CLIA waiver trial for FebriDx in the US, and achieve FDA label extension

Continue to build the foundation for long-term growth through strategic partnerships, and delivering on milestones relating to the Hologic fFN development agreement

Initiate product development on Lumos branded women's health diagnostics tests.

LUMOS

DIAGNOSTICS

www.lumosdiagnostics.com